Becton, Dickinson and Company
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BDX research report →
Companywww.bd.com
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.
- CEO
- Thomas E. Polen Jr.
- IPO
- 1973
- Employees
- 70,000
- HQ
- Franklin Lakes, NJ, US
Price Chart
Valuation
- Market Cap
- $53.24B
- P/E
- 36.24
- P/S
- 2.49
- P/B
- 1.71
- EV/EBITDA
- 16.74
- Div Yield
- 2.39%
Profitability
- Gross Margin
- 46.48%
- Op Margin
- 10.61%
- Net Margin
- 5.33%
- ROE
- 4.54%
- ROIC
- 4.10%
Growth & Income
- Revenue
- $21.84B · 8.23%
- Net Income
- $1.68B · -1.58%
- EPS
- $5.84 · -0.68%
- Op Income
- $2.58B
- FCF YoY
- -13.09%
Performance & Tape
- 52W High
- $187.35
- 52W Low
- $127.59
- 50D MA
- $153.40
- 200D MA
- $154.47
- Beta
- 0.28
- Avg Volume
- 2.92M
Get TickerSpark's AI analysis on BDX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 8, 26 | Huffines Robert Luther | other | 210 |
| May 8, 26 | Byington Carrie L | other | 105 |
| May 7, 26 | Roque Vitor | other | 1,721 |
| Apr 27, 26 | Feld Michael | sell | 74 |
| Apr 6, 26 | Neal Shana Carol | other | 1,146 |
| Mar 26, 26 | Feld Michael | sell | 75 |
| Mar 16, 26 | Minnix Lanesha | other | 7,492 |
| Mar 16, 26 | Minnix Lanesha | other | 0 |
| Mar 2, 26 | Roque Vitor | other | 931 |
| Mar 2, 26 | Spikner Pamela L. | other | 931 |
Our BDX Coverage
We haven't published any research on BDX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BDX Report →